ICN expands Senetek's Kinerase license
agreement which amends its current manufacturing license with
Senetek to expand ICN's moisturising Kinerase product line.
ICN Pharmaceuticals has announced the signing of a license agreement which amends its current manufacturing license with Senetek to expand ICN's moisturising Kinerase product line. The new license covers kinetin (N6-furfuryladenine)-containing products in North America, Europe and Australia.
The expanded contract adds five new products to the Kinerase line, including new serum and cream formulations with highly stabilised Vitamin C, a Kinerase sunscreen formulation and new cream and lotion formulations. ICN has licensed the rights to both manufacture and advertise the products, said the company in a statement.
"This expanded license underscores ICN's commitment to dermatology as a worldwide therapeutic area of focus, and demonstrates our willingness to commit worldwide resources to the product line," said Tim Tyson, ICN's chief operating officer and president.
Available in both a cream and lotion formulation, Kinerase is sold by approximately 2,500 dermatologists and plastic surgeons throughout the United States and Canada for improving the appearance and texture of sun-damaged facial skin and providing gentle moisturisation for a variety of skin types.
ICN is a research-based global pharmaceutical company making a broad range of prescription and non-prescription pharmaceuticals as well as cosmetics under the ICN brand name. Its research and new product development focuses on treatments for dermatology, infectious diseases and cancer.
